R&D on the cash flow statement: expense, payments and assets

R&D cash flow statement treatment starts by separating expense from payments: research and development expense generally affects operating cash flow, while qualifying asset purchases can affect investing cash flow. Under the indirect method, net income already includes R&D expense, so adjust for its noncash components and payment timing rather than adding back the whole amount. A project cost report alone cannot show the cash outflow.

What is expense and what is cash

US GAAP generally expenses research and development costs as incurred. That expense can include payroll, contractors, laboratory supplies, depreciation and stock compensation, which do not all have the same relationship to current cash. For a primary-source example, Amgen's fiscal 2025 financial statements state that R&D costs are expensed as incurred and describe staff, facilities, clinical trial and other costs, including amortization of certain acquired technology with alternative future uses.

Paid employee salaries and payments for research services are ordinarily operating cash outflows. Equipment purchased and recognized as a long-lived asset is a different transaction. Its purchase can be investing cash flow even though the equipment is used by researchers, while depreciation later enters their department's expense.

The SEC's guide to cash flow statements explains the distinction between operating reconciliations, noncash adjustments and purchases of long-term assets in investing activities. Use the cash flow statement example for the full statement structure; this article works the project-level bridge behind it.

Reconcile the project schedule to the ledger first

Start with the R&D general ledger detail, payroll cost allocation, supplier invoice register, opening and closing accruals, prepaid expense movements and asset additions schedule. Keep a project identifier, cost center, service period, posting date, cash settlement date, currency and controller-approved expense or asset classification on the relevant rows.

First agree project expense totals to the R&D income-statement line. Then identify noncash components and reconcile unpaid balances. Reclassifications between departments need to balance across the company; otherwise project totals can change without a corresponding company expense change.

The accrual versus cash accounting example explains the general timing bridge. For R&D, the practical complication is that internal labor, outside services and asset purchases often arrive in different exports. A purchase order commitment is useful for planning but is not automatically an expense, liability or cash payment.

A worked R&D expense-to-cash bridge

Harbor Instruments, a fictional US company, reviews three projects for the quarter ended September 30, 2026. The company has no R&D prepayments, recoveries, foreign currency effects or other adjustments. All stock compensation is noncash equity-settled expense, and the accrued liabilities below relate only to otherwise cash-payable R&D costs.

R&D operating cash paid = R&D expense - Noncash expense + Opening R&D operating accruals - Closing R&D operating accruals

With prepayments, add their increase or subtract their decrease after excluding unrelated and noncash movements. The example has none, so its bridge is:

Discovery cash paid is 300,000 - 30,000 - 20,000 + 40,000 - 60,000 = $230,000. The same calculation gives $390,000 for Prototype and $160,000 for Platform. Adding those cash amounts produces $780,000.

The total-column check gives the same answer: 1,000,000 - 100,000 - 60,000 + 120,000 - 180,000 = $780,000. Every amount is an exact whole-dollar figure, with no rounding. Agree the result to payments identified in the payroll and supplier settlement records.

The $220,000 gap between expense and operating cash paid consists of $160,000 of noncash expense and a $60,000 increase in unpaid accruals. That second part is delayed payment, not a permanent reduction in project cost. The stock-compensation cash flow reconciliation covers the separate award expense and settlement checks.

Add qualifying capital spending separately

Harbor also pays for reusable laboratory equipment and qualifying internal-use software development costs for its research operations. Its controller has approved asset recognition under the applicable policies. These costs are excluded from the expense table above, and the example has no unpaid capital additions.

Capitalization is not available just because management expects a project to be valuable. Specific criteria apply. For example, Microsoft's fiscal 2025 accounting policy includes software developed or acquired for internal use within property and equipment. It describes a separate policy for software sold externally, with capitalization after technological feasibility. Those policies should not be applied interchangeably.

Capitalization also does not automatically make a payment investing. Take-Two's fiscal 2026 cash flow statement includes software development costs and licenses in operating asset movements. Harbor's investing example specifically uses internal-use software, not software products developed for sale. Confirm both the accounting policy and cash classification before combining project schedules.

Harbor's project-related cash use is $780,000 of operating payments plus $320,000 of investing payments, totaling $1,100,000. An expense-only report shows $1,000,000, so it misses both the noncash and timing bridge and the separately capitalized payments.

An additional asset check supports the schedule:

There are no disposals, impairments, amortization or other asset movements in this example. The check is 600,000 + 320,000 - 60,000 = $860,000. The depreciation deduction here explains the asset balance; its operating add-back reverses the same noncash expense and does not create a second cash flow.

What the reconciled figure changes

The controller owns accounting recognition and cash flow classification. Project leaders validate the work performed and coding, procurement supports supplier obligations, and treasury confirms settlements. FP&A compares expense, payment timing and capital commitments when reviewing funding needs.

Prototype has the largest operating cash payments at $390,000, but its closing accrual of $90,000 also matters for the next period's liquidity. Put the expected settlement dates into the cash flow forecast. Comparing only current payments could mistake a growing unpaid balance for better spending control.

Where it goes wrong

• Adding back all R&D expense. Only noncash components and appropriate balance movements adjust net income. Cash operating costs remain cash costs.
• Capitalizing every development project. Use the applicable US accounting policy and approved supporting facts, not the department name or a desired profit outcome.
• Counting capital additions twice. Exclude capitalized costs from the expense bridge before adding their investing cash payments.
• Ignoring supplier and payroll timing. Opening liabilities can produce current cash outflows, while closing liabilities defer them.
• Substituting tax treatment for financial reporting. Tax deductions and capitalization can follow different rules. Use the financial-reporting schedules for this reconciliation.

Reconcile your R&D workbook in Covirage

Upload a file with project expenses, accrual movements, cash payments and approved asset classifications; Covirage maps the columns, and its tools compute and check the reconciliations. The external AI model explains the result with every figure traced to its rows. Create a free Covirage account and bring a sample of your own export.

See Covirage for finance teams for the broader reporting context.